ICW Healthcare Ventures
ICW Ventures is dedicated to uncovering solutions that others could not find, aiming to deliver game-changing health technologies that improve life for everyone. They focus on identifying and developing HealthTech breakthroughs, including innovative vaccines and diagnostic devices, with a mission to create equitable and impactful health solutions.
Industries
Nr. of Employees
small (1-50)
ICW Healthcare Ventures
Products
EdJen Biotech peptide vaccine platform
A vaccine development platform that identifies conserved pathogen peptides and formulates peptide-only vaccines intended to induce protective immunity while excluding whole pathogen structures or genetic material.
Therapeutic peptide program (MANP analog)
Development of an engineered atrial natriuretic peptide analog intended to activate GC-A receptor pathways, evaluated in first-in-human studies for blood pressure lowering and related cardiometabolic effects.
Portable rapid molecular diagnostic devices (Genomadix)
Development of portable, rapid molecular diagnostic devices aimed at decentralizing molecular testing.
EdJen Biotech peptide vaccine platform
A vaccine development platform that identifies conserved pathogen peptides and formulates peptide-only vaccines intended to induce protective immunity while excluding whole pathogen structures or genetic material.
Therapeutic peptide program (MANP analog)
Development of an engineered atrial natriuretic peptide analog intended to activate GC-A receptor pathways, evaluated in first-in-human studies for blood pressure lowering and related cardiometabolic effects.
Portable rapid molecular diagnostic devices (Genomadix)
Development of portable, rapid molecular diagnostic devices aimed at decentralizing molecular testing.
Services
Identification and development of early-stage HealthTech projects and ventures, including strategic guidance and project-level support.
Advisory services for chemistry, manufacturing and control (CMC) development, analytical method design, formulation, and preparation for regulatory filings.
Support for early-phase clinical study design and execution, including first-in-human trial planning and safety/tolerability study designs.
Facilitation of public-health and industry partnerships and support for commercialization strategy and licensing negotiations.
Identification and development of early-stage HealthTech projects and ventures, including strategic guidance and project-level support.
Advisory services for chemistry, manufacturing and control (CMC) development, analytical method design, formulation, and preparation for regulatory filings.
Support for early-phase clinical study design and execution, including first-in-human trial planning and safety/tolerability study designs.
Facilitation of public-health and industry partnerships and support for commercialization strategy and licensing negotiations.
Expertise Areas
- Peptide-based vaccine development
- Peptide therapeutics development
- Mass spectrometry-based epitope mapping
- Immunogenicity testing and preclinical validation
Key Technologies
- Mass spectrometry (peptide mapping)
- ELISA and immunoassays
- In silico epitope prediction (bioinformatics)
- Peptide engineering
News & Updates
A recent analysis highlights the unmet need in blood pressure control in hypertension. The study discusses the potential of novel ANP-based therapy, specifically MANP, which has shown promise in reducing blood pressure and related biological effects.
A study demonstrates that a single subcutaneous injection of M-atrial natriuretic peptide (MANP) is safe, well-tolerated, and exerts blood pressure-lowering, lipolytic, and insulin resistance–improving effects in patients with hypertension and metabolic syndrome.
The first-in-human study reports that MANP is safe, well tolerated, and activates cGMP, induces natriuresis, reduces aldosterone, and decreases blood pressure in hypertensive subjects.
Research on peptide-based vaccine development for SARS-CoV-2, focusing on identification, validation, and immunogenicity of conserved peptides.
Study on peptide-based smallpox vaccine design through immunogenicity evaluation of T-cell epitopes.
Research on detecting SARS-CoV-2 peptide-specific antibodies using ELISA in Syrian hamsters.
A recent analysis highlights the unmet need in blood pressure control in hypertension. The study discusses the potential of novel ANP-based therapy, specifically MANP, which has shown promise in reducing blood pressure and related biological effects.
A study demonstrates that a single subcutaneous injection of M-atrial natriuretic peptide (MANP) is safe, well-tolerated, and exerts blood pressure-lowering, lipolytic, and insulin resistance–improving effects in patients with hypertension and metabolic syndrome.
The first-in-human study reports that MANP is safe, well tolerated, and activates cGMP, induces natriuresis, reduces aldosterone, and decreases blood pressure in hypertensive subjects.
Research on peptide-based vaccine development for SARS-CoV-2, focusing on identification, validation, and immunogenicity of conserved peptides.
Study on peptide-based smallpox vaccine design through immunogenicity evaluation of T-cell epitopes.
Research on detecting SARS-CoV-2 peptide-specific antibodies using ELISA in Syrian hamsters.